Merck Announces Presentation of Results from Two Phase 2 Studies of...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the initial phase...
View ArticleData from ALLY-3+ Trial Investigating Daklinza (daclatasvir) in Combination...
(Source: Bristol-Myers Squibb Company) PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced late-breaking data from the Phase 3 ALLY-3+ trial investigating a...
View ArticleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies...
NORTH CHICAGO, Ill., Nov. 16, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data from the SURVEYOR studies of its investigational HCV regimen, ABT-493,...
View ArticleAbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Nov. 16, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced data from the SURVEYOR studies of its investigational...
View Article"Friends" of the Liver Center Announce Diamonds Gala: “Mission: Possible”...
(Source: Saint Louis University) The Friends of the Saint Louis University Liver Center invite the public in joining them as they celebrate the 13th Annual Diamonds Gala. This year's event - entitled...
View ArticleAbbVie's Leadership and Innovation in Immunology Showcased at the American...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Nov. 3, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational...
View ArticleFirst Investigational All Injectable Long Acting HIV Combination Regimen...
(Source: Johnson & Johnson) 4276210d-1972-426f-bab1-761478e35fc7.pdf November 3, 2015 First Investigational All Injectable Long Acting HIV Combination Regimen Study Results at 32 Weeks Announced...
View ArticleIntercept Pharmaceuticals Announces Results of Phase 2 Trial of OCA in NASH...
(Source: Intercept Pharmaceuticals Inc) NEW YORK, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the...
View ArticleRoche expands cobas 4800 System menu with HIV-1, HCV and HCV Genotyping Tests...
(Source: Roche Holding AG) Basel, 3 November 2015 Roche expands cobas 4800 System menu with HIV-1, HCV and HCV Genotyping Tests System portfolio broadens to include high medical value virology assays...
View ArticleNovember 4, 2015 - Transgene Announces Dosing of First Patient with TG1050...
(Source: Transgene SA) 50f21935-50e1-40d7-b527-17e2187026e1.pdf Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection Strasbourg, France, November 4,...
View ArticleThis Is Why Hepatitis C Drugs Are So Expensive
Earlier this week, actress Pamela Anderson announced that she's been cured of hepatitis C. She shared the news in a joyful (and racy) Instagram post that proclaimed, "I am CURED,” but also acknowledged...
View ArticlePamela Anderson goes nude to celebrate being cured of hepatitis C
When former Baywatch beauty Pamela Anderson contracted hepatitis C after sharing a tattoo needle with (then) husband Tommy Lee 16-years ago, she viewed the diagnosis as a death sentence. Now, however,...
View ArticleJudge increases compensation for woman over hep C infection
A judge has increased to €250,000 a sum of €180,000 compensation awarded to a woman who suffered “life-destroying” side effects, including a brain injury, following treatment to deal with being...
View ArticleConatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD...
(Source: Conatus Pharmaceuticals Inc) - Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis - - Emricasan Significantly Lowered Portal Pressure in...
View ArticleResearchers create index to aid liver cancer risk analysis
A Taiwanese medical research team said that it has developed an index of five critical-risk factors used to predict the risk of developing liver cancer from hepatitis C in a five-to-5 year period....
View ArticleGenentech to Present New Clinical Data Across a Variety of Blood Diseases at...
(Source: Genentech Inc) / Media Thursday, Nov 5, 2015 South San Francisco, CA -- November 5, 2015 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that more than...
View ArticleStudy: Three-drug combos eliminate hepatitis C virus genotype 1b infection in...
(Source: Emory University) A pilot study has found that a combination of drugs used to treat the hepatitis C virus could substantially reduce the time of treatment to as little as three weeks for some...
View ArticleAbbVie Reports Third-Quarter 2015 Financial Results - Reports Third-Quarter...
, Oct. 30, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the third quarter ended September 30, 2015. "We are pleased with our outperformance in the third quarter and our...
View ArticleThe Dark Side of Letting Insurance Payers Dictate Hepatitis C Treatment
Imagine that you have a disease and you have two choices of treatment. Both treatments are highly effective at treating your condition. Medication A has mild side effects. Medication B has lots of side...
View ArticleConatus Pharmaceuticals Reports Third Quarter 2015 Financial Results and...
(Source: Conatus Pharmaceuticals Inc) SAN DIEGO, Nov. 4, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of...
View Article